Home > Expanded Access > Expanded Access for CC-486

Celgene

Expanded Access for CC-486

Official Title: 
Expanded Access for CC-486
Brief Summary: 
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.
Available
EA Type
Individual Patients
Myelodysplastic Syndrome (MDS)

Drug: CC-486
Oral azacitidine administered as directed by treating physician.
Other Name: Oral Azacitidine

Eligibility Criteria: 

Inclusion Criteria:

-

Exclusion Criteria:

-

Eligibility Gender: 
All
Countries: 
United States
Locations: 

Celgene
Summit, New Jersey, 07901

Contacts: 

Celgene Medical Information
1-888-771-0141
medinfo@celgene.com

EA Number: 
Keywords: 
Expanded Access, Compassionate Use
MeSH Terms: 
Myelodysplastic Syndromes, Preleukemia, Azacitidine
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.